Last reviewed · How we verify
NCT07173803: PTP
The Progressive Supranuclear Palsy Clinical Trial Platform
Phase 2 trial testing AADvac1 in Progressive Supranuclear Palsy(PSP) in 440 participants. Not yet recruiting.
31 July 2029
Quick facts
| Lead sponsor | Adam Boxer |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 440 |
| Start date | 1 December 2025 |
| Primary completion | 31 July 2029 |
| Estimated completion | 31 July 2029 |
Drugs / interventions tested
Conditions studied
- Progressive Supranuclear Palsy(PSP) — all drugs for Progressive Supranuclear Palsy(PSP) →
Sponsor
Adam Boxer — full company profile →
Who can join
Adults 41 to 86, any sex, with Progressive Supranuclear Palsy(PSP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07173803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AADvac1
Trials testing the same drug.
- NCT07167966 — Alzheimer's Tau Platform: Regimen A - AADvac1 · Phase 2 · not yet recruiting
- NCT06957418 — Alzheimer's Tau Platform: Master Protocol · Phase 2 · not yet recruiting
- NCT07217665 — The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 · Phase 2 · not yet recruiting
Other recruiting trials for Progressive Supranuclear Palsy(PSP)
Currently open trials in the same condition.
- NCT06647641 — The CurePSP Genetics Program · recruiting
- NCT06949865 — AI-Enhanced Optimization of Acute Levodopa Challenge Test · recruiting
- NCT07392411 — Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Bioma · recruiting
- NCT04715399 — UPenn Observational Research Repository on Neurodegenerative Disease · recruiting
Other Adam Boxer trials
Trials by the same sponsor.
- NCT07264283 — The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 · Phase 2 · not yet recruiting
- NCT07217665 — The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 · Phase 2 · not yet recruiting
- NCT03277573 — Salsalate in Patients Mild to Moderate Alzheimer's Disease · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07173803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Adam Boxer
- Last refreshed: 2 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07173803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing